公开(公告)号：US20170232089A1

公开(公告)日：2017-08-17

申请号：US15530247

申请日：2016-12-16

申请人： INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

发明人： Haruo Sugiyama

IPC分类号： A61K39/00

CPC分类号： A61K39/0011 ,  A61K35/15 ,  A61K35/17 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C07K7/06 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639 ,  C12N2501/40 ,  G01N33/56972 ,  G01N33/574 ,  G01N33/57496

摘要： A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.

公开(公告)号：US20170219589A1

公开(公告)日：2017-08-03

申请号：US15483297

申请日：2017-04-10

申请人： The Children's Medical Center Corporation ,  The U.S.A., As Represented by the Secretary, Department of Health & Human Services

发明人： Anjana Rao ,  Mamta Tahiliani ,  Kian Peng Koh ,  Suneet Agarwal ,  Aravind Iyer

IPC分类号： G01N33/574 ,  G01N33/53

CPC分类号： C12Q1/6827 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0637 ,  C12N5/0696 ,  C12N9/0071 ,  C12N15/873 ,  C12N2501/15 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/70 ,  C12N2501/71 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2510/00 ,  C12Q1/26 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2521/531 ,  C12Q2522/10 ,  C12Q2537/164 ,  C12Q2600/154 ,  G01N33/5011 ,  G01N33/5308 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2500/00

摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

公开(公告)号：US20170211072A1

公开(公告)日：2017-07-27

申请号：US15321561

申请日：2015-06-25

申请人： Cold Spring Harbor Laboratory ,  Rutgers, The State University of New Jersey

发明人： Raffaella Sordella ,  Serif Senturk ,  Luca Cartegni

IPC分类号： C12N15/113 ,  A61K31/713 ,  G01N33/574 ,  A61K38/13 ,  A61K45/06

CPC分类号： C12N15/1137 ,  A61K31/198 ,  A61K31/445 ,  A61K31/713 ,  A61K38/13 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2320/31 ,  C12Y502/01008 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57496 ,  G01N2333/4748 ,  G01N2800/52 ,  A61K2300/00

摘要： Provided herein are methods and compositions for inhibiting epithelial to mesenchymal transition of a cell.

公开(公告)号：US20170204472A1

公开(公告)日：2017-07-20

申请号：US15475344

申请日：2017-03-31

申请人： Dignity Health ,  The Translational Genomics Research Institute

发明人： Shwetal V. Mehta ,  Michael E. Berens ,  Harshil Dineshkumar Dhruv

IPC分类号： C12Q1/68 ,  A61K31/495 ,  G01N33/574 ,  A61K31/131

CPC分类号： C12Q1/6886 ,  A61K31/131 ,  A61K31/495 ,  C12Q2565/501 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Y302/02021 ,  C12Y402/99018 ,  G01N33/57407 ,  G01N33/57496 ,  G01N2333/924 ,  G01N2333/988 ,  Y02A50/473

摘要： The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.

公开(公告)号：US20170176446A1

公开(公告)日：2017-06-22

申请号：US15404473

申请日：2017-01-12

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  Affichem

发明人： Philippe De Medina ,  Michael Paillasse ,  Marc Poirot ,  Sandrine Silvente-Poirot

IPC分类号： G01N33/574 ,  A61K31/138 ,  A61K31/40 ,  A61K31/58 ,  A61K31/4535 ,  A61K31/565 ,  A61K31/4515 ,  A61K31/135 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/496 ,  A61K31/343 ,  A61K31/5415 ,  A61K31/5685 ,  A61K31/195 ,  G01N33/92

CPC分类号： G01N33/57496 ,  A61K31/135 ,  A61K31/138 ,  A61K31/195 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4515 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/565 ,  A61K31/5685 ,  A61K31/58 ,  G01N33/5091 ,  G01N33/57484 ,  G01N33/92 ,  G01N2405/00

摘要： The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.

公开(公告)号：US20170176421A1

公开(公告)日：2017-06-22

申请号：US15440408

申请日：2017-02-23

申请人： The Children's Medical Center Corporation ,  The United States of America, As Represented by the Secretary, Department of Health & Human Servic

发明人： Anjana Rao ,  Mamta Tahiliani ,  Kian Peng Koh ,  Suneet Agarwal ,  Aravind Iyer

IPC分类号： G01N33/53 ,  C12N5/074 ,  G01N33/574

CPC分类号： C12Q1/6827 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0637 ,  C12N5/0696 ,  C12N9/0071 ,  C12N15/873 ,  C12N2501/15 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/70 ,  C12N2501/71 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2510/00 ,  C12Q1/26 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/154 ,  G01N33/5011 ,  G01N33/5308 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2500/00 ,  C12Q2537/164 ,  C12Q2522/10 ,  C12Q2521/531

摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

公开(公告)号：US20170176413A1

公开(公告)日：2017-06-22

申请号：US15445975

申请日：2017-02-28

申请人： The United States of America, as represented by the Secretary, Department of Health & Human Servic

发明人： Eun J. Chung ,  Jane Trepel

IPC分类号： G01N33/50 ,  G01N33/574

CPC分类号： G01N33/5011 ,  G01N33/57496 ,  G01N2333/98 ,  G01N2440/10

摘要： The present disclosure provides a method of monitoring total protein acetylation in a cell exposed to an HDAC inhibitor that involves first contacting a cell that has been exposed to an HDAC inhibitor with a plurality of reagents that each recognize and bind to a nuclear or cytoplasmic acetylated protein. The bound reagent is then detected using a detection assay and the level of the detected bound reagent is compared to a control, thereby monitoring total protein acetylation in the cell.

公开(公告)号：US20170146535A1

公开(公告)日：2017-05-25

申请号：US15363832

申请日：2016-11-29

申请人： Spring BioScience Corporation

发明人： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC分类号： G01N33/573 ,  G01N33/574 ,  C12N9/96 ,  C07K16/40 ,  C12N9/02

CPC分类号： G01N33/573 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/567 ,  C12N9/0069 ,  C12N9/96 ,  C12Y113/11052 ,  G01N33/57496 ,  G01N2333/90241

摘要： The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

公开(公告)号：US09657092B2

公开(公告)日：2017-05-23

申请号：US14553554

申请日：2014-11-25

申请人： LYKERA BIOMED SA

发明人： Jose Luis Hernandez Miguez ,  Jaume Adan Plana ,  Josep Maria Martinez Escola ,  Marc Masa Alvarez ,  Ramon Messeguer Peypoch ,  Francesc Mitjans Prat ,  Sheila Dakhel Plaza ,  Antonio Coll Manzano ,  Rosa Ma Hervas Villegas ,  Carme Calvis Calpe ,  Laura Padilla Garcia ,  Lourdes Tatiana Roque Navarro ,  Laura Barbera Ferrando ,  Manuel Rivas Canas ,  Luis Angel Gomez Casajus

IPC分类号： C07K16/18 ,  A61K39/395 ,  G01N33/574 ,  G01N33/68 ,  A61K45/06 ,  C07K16/30 ,  A61K31/7068 ,  A61K39/00

CPC分类号： C07K16/18 ,  A61K31/7068 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/57488 ,  G01N33/57496 ,  G01N33/6893 ,  A61K2300/00

摘要： The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.

公开(公告)号：US09645136B2

公开(公告)日：2017-05-09

申请号：US14591678

申请日：2015-01-07

申请人： DANA-FARBER CANCER INSTITUTE, INC.

发明人： David Pellman

IPC分类号： C12Q1/68 ,  G01N33/50 ,  A61K31/7088 ,  A61K31/7105 ,  G01N33/574 ,  C12N5/00

CPC分类号： G01N33/5011 ,  A61K31/7088 ,  A61K31/7105 ,  G01N33/5026 ,  G01N33/57496 ,  G01N2333/914 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

摘要： The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provided.